BAXTER INTERNATIONAL INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.2B | $10.6B | $10.4B | $10.1B | $12.1B |
| Cost of revenue | $7.9B | $6.7B | $6.2B | $6.5B | $7.4B |
| Gross profit | $3.4B | $4.0B | $4.2B | $3.5B | $4.7B |
| Selling, general & administrative | $2.9B | $3.0B | $3.0B | $3.1B | $2.8B |
| Research and development | $518.0M | $590.0M | $518.0M | $450.0M | $531.0M |
| Operating income | -$308.0M | $14.0M | $707.0M | -$2.8B | $1.4B |
| Interest expense | $290.0M | $408.0M | $508.0M | $413.0M | $207.0M |
| Pretax income | -$505.0M | -$289.0M | $242.0M | -$3.2B | $1.1B |
| Income tax expense | $395.0M | $37.0M | $61.0M | -$135.0M | $83.0M |
| Net income | -$957.0M | -$649.0M | $2.7B | -$2.4B | $1.3B |
| Balance Sheet | |||||
| Cash and equivalents | $2.0B | $1.8B | $3.1B | $1.6B | $3.0B |
| Current assets | $6.9B | $8.9B | $9.6B | $8.0B | $8.9B |
| Total assets | $20.1B | $25.8B | $28.3B | $28.3B | $33.5B |
| Current liabilities | $3.0B | $6.5B | $6.5B | $4.7B | $4.2B |
| Total liabilities | $14.0B | $18.8B | $19.8B | $22.4B | $24.4B |
| Total debt | $9.5B | — | — | — | — |
| Stockholders' equity | $6.1B | $7.0B | $8.4B | $5.8B | $9.1B |
| Cash Flow Statement | |||||
| Cash from operations | $845.0M | $1.0B | $1.7B | $1.2B | $2.2B |
| Depreciation and amortization | $981.0M | $997.0M | $984.0M | $1.1B | $867.0M |
| Stock-based compensation | $117.0M | $114.0M | $115.0M | $140.0M | $146.0M |
| Capital expenditure | $513.0M | $446.0M | $432.0M | $377.0M | $691.0M |
| Free cash flow | $332.0M | $573.0M | $1.3B | $834.0M | $1.5B |
| Dividends paid | $348.0M | $590.0M | $586.0M | $573.0M | $530.0M |
| Share repurchases | — | $0 | $0 | $32.0M | $600.0M |
| Impairments | $485.0M | $425.0M | $0 | $2.8B | $0 |
Shares outstanding 516.5M · Free float 94.9%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.
Earnings
Other Coverage
July 20, 2026
FDA
Baxter Recalls Hillrom Volara Patient Circuits
July 20, 2026
FDA
Baxter Recalls Hillrom Volara Patient Circuit
July 20, 2026
FDA
Baxter Recalls Hillrom Volara Circuit Kits in Class I Action
July 20, 2026
FDA
Baxter Recalls Hillrom VOLARA Circuit Kit
July 16, 2026
Small-Cap Signal
AI Infrastructure Pivot Trumps Legacy Cloud Resale